In information available today on its website, Infarmed explains that the decision came from a complaint received regarding Cannabiron CBD creams, from the company Dietmed, and Good Cannabis, from Vitaceutics.

The National Authority for Medicines and Health Products recalls the 2022 circular regarding the use of cannabis and its derivatives in cosmetic products.

It also explains that the creams in question have cannabidiol in their composition, which is obtained through extracts or tinctures of cannabis or its resin and is not permitted in the composition of cosmetic products.

"Entities that have these products should not make them available" and consumers who have these products "should not use them", recommends Infarmed.